CHROMADEX CORPORATION (NASDAQ:CDXC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

CHROMADEX CORPORATION (NASDAQ:CDXC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Item 5.02


Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

(e) The Board of Directors of ChromaDex Corporation (the Company)
previously approved the ChromaDex Corporation 2017 Equity
Incentive Plan (the 2017 Plan), subject to approval by the
stockholders of the Company. The 2017 Plan is intended to be the
successor to the ChromaDex Corporation Second Amended and
Restated 2007 Equity Incentive Plan. On June 20, 2017, the
stockholders of the Company approved the 2017 Plan.

A detailed summary of the material terms and conditions of the
2017 Plan is set forth under the heading Proposal 2: Approval of
the ChromaDex Corporation 2017 Equity Incentive Plan in the
Companysdefinitive proxy statement for the Companys 2017 Annual
Meeting of Stockholders filed with the Securities and Exchange
Commission on May 1, 2017 (the Proxy Statement), which is
incorporated herein by reference. The foregoing description of
the 2017 Plan and the summary of the 2017 Plan included in the
Proxy Statement are not complete and are qualified in their
entirety by reference to the full text of the 2017 Plan, which is
filed herewith as Exhibit 99.1.
Item 5.07

Submission of Matters to a Vote of Security Holders.


Set forth below are the results of the matters submitted for a
vote of stockholders at the Companys 2017 Annual Meeting of
Stockholders held on June 20, 2017.

Proposal 1 Election of directors.

The following directors were elected to serve until the Companys
2018 Annual Meeting of Stockholders and until his or her
successor is elected, or, if sooner, until such directors death,
resignation or removal.
DirectorElected
For

Withheld

BrokerNon-Votes

Stephen Allen
20,526,391
102,607
12,678,171
Frank L. Jaksch Jr.
20,521,691
107,307
12,678,171
Stephen Block
20,526,390
102,608
12,678,171
Jeff Baxter
20,521,691
107,307
12,678,171
Robert Fried
20,526,390
102,608
12,678,171
Kurt Gustafson
20,521,690
107,308
12,678,171
Steven Rubin
20,526,391
102,607
12,678,171

Proposal 2 Approval of ChromaDex Corporation 2017 Equity
Incentive Plan.
For

Against

Abstain

BrokerNon-Votes

19,302,476
1,036,211
290,310
12,678,172

Proposal 3 Ratification of the appointment of Marcum LLP
as the Company’s independent registered public
accounting firm for the fiscal year ending December 30,
2017.
For

Against

Abstain

BrokerNon-Votes

32,666,330
360,162
280,677
Item 9.01

Financial Statements and Exhibits.


(d)Exhibits.


Exhibit Number


Description


99.1

ChromaDex Corporation 2017 Equity Incentive Plan.




ChromaDex Corp. Exhibit
EX-99.1 2 cdxc_991.htm CHROMADEX CORPORATION 2017 EQUITY INCENTIVE PLAN. Blueprint   Exhibit 99.1   ChromaDex Corporation 2017 Equity Incentive Plan   Adopted by the Board of Directors: April 6,…
To view the full exhibit click here
About CHROMADEX CORPORATION (NASDAQ:CDXC)

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

An ad to help with our costs